Skip to content
10-Q

Quarterly Report

Coeptis Therapeutics, Inc.

0001683168-22-003496

← back to feed
Filed
May 12, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · May 11, 2022 38.69M sh
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$961.73K
Long Term Debt Q1 2022 · Mar 31, 2022 $1.65M
Long Term Debt Q1 2022 · Dec 31, 2021 $1.65M
Stockholders Equity Q1 2022 · Mar 31, 2022 $2.34M
Stockholders Equity Q1 2022 · Dec 31, 2021 $2.35M
Current Liabilities Q1 2022 · Mar 31, 2022 $2.71M
Current Liabilities Q1 2022 · Dec 31, 2021 $2.76M
Total Liabilities Q1 2022 · Mar 31, 2022 $4.41M
Total Liabilities Q1 2022 · Dec 31, 2021 $4.41M
Current Assets Q1 2022 · Mar 31, 2022 $2.34M
Current Assets Q1 2022 · Dec 31, 2021 $2.18M
Total Assets Q1 2022 · Mar 31, 2022 $6.75M
Total Assets Q1 2022 · Dec 31, 2021 $6.77M
Sga Expense Q1 2022 · Mar 31, 2022 $15.72M
Rd Expense Q1 2022 · Mar 31, 2022 $0
Net Income Q1 2022 · Mar 31, 2022 −$19.18M
Operating Income Q1 2022 · Mar 31, 2022 −$15.77M
Gross Profit Q1 2022 · Mar 31, 2022 $0
Cost Of Revenue Q1 2022 · Mar 31, 2022 $0
Revenue Q1 2022 · Mar 31, 2022 $0